Lamictal Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144547 GLAXOSMITHKLINE LLC Oral dosage form for controlled drug release
Sep, 2023

(8 days ago)

US8637512 GLAXOSMITHKLINE LLC Formulations and method of treatment
Jun, 2028

(4 years from now)

Lamictal Xr is owned by Glaxosmithkline Llc.

Lamictal Xr contains Lamotrigine.

Lamictal Xr has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Lamictal Xr are:

  • US9144547

Lamictal Xr was authorised for market use on 29 May, 2009.

Lamictal Xr is available in tablet, extended release;oral dosage forms.

The generics of Lamictal Xr are possible to be released after 14 June, 2028.

Drugs and Companies using LAMOTRIGINE ingredient

Market Authorisation Date: 29 May, 2009

Treatment: NA


How can I launch a generic of LAMICTAL XR before it's drug patent expiration?
More Information on Dosage

LAMICTAL XR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic